Jim Cramer of CNBC discussed the extreme post-election market, noting big wins and losses in various sectors. He highlighted the sharp rise of enterprise software stocks like Salesforce and cautioned against buying at current levels. Cramer also mentioned sectors that are “too hated,” such as pharmaceuticals and semiconductors, suggesting they could bounce back with more clarity from President-elect Trump.
Full Article
Lenz (LENZ) Q2 Revenue Jumps 604%
Lenz Therapeutics (NASDAQ:LENZ) reported second quarter 2025 results on July 30, revealing $5.0 million in GAAP revenue from licensing milestones, significantly surpassing analyst expectations. Despite a deeper net loss due to increased spending, the company made strides in its commercial plans ahead of an important FDA decision for its lead product, LNZ100, aimed at treating presbyopia. Want More Context? 🔎
Read more